Shi Jiang
Impact in
- Infectious Diseases top 0.01%
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Viral gastroenteritis research and epidemiology
- HIV/AIDS drug development and treatment
- Virology top 0.05%
- HIV Research and Treatment
Papers in
-
- SARS-CoV-2 and COVID-19 Research 205
- HIV/AIDS drug development and treatment 131
- COVID-19 Clinical Research Studies 80
- Viral gastroenteritis research and epidemiology 72
- Virology 192
- HIV Research and Treatment 189
- Co-authors
- Lanying Du (124 shared papers)Shuwen Liu (71 shared papers)Lu Lu (177 shared papers)Yusen Zhou (63 shared papers)Yuxian He (41 shared papers)Hong Lü (54 shared papers)Shuai Xia (53 shared papers)Asim Kumar Debnath (29 shared papers)
- Journals
- Journal of Virology (24 papers)Viruses (24 papers)Microbes and Infection (23 papers)Biochemical and Biophysical Research Communications (18 papers)Journal of Medicinal Chemistry (18 papers)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Shi Jiang
570 papers receiving 34.2k citations
Shi Jiang's Hit Papers
Peers
Comparison fields: 5 of 203
- Infectious Diseases 22.7k
- Virology 4.9k
- Animal Science and Zoology 4.5k
- Immunology 4.6k
- Modeling and Simulation 886
Countries citing papers authored by Shi Jiang
This map shows the geographic impact of Shi Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shi Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shi Jiang more than expected).
Fields of papers citing papers by Shi Jiang
This network shows the impact of papers produced by Shi Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shi Jiang. The network helps show where Shi Jiang may publish in the future.
Co-authors
The 25 scholars most cited alongside Shi Jiang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 585 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The spike protein of SARS-CoV — a target for vaccine and therapeutic development Hit paper breakdown → | 2009 | 1319 |
| 2 | Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine Hit paper breakdown → | 2020 | 1301 |
| 3 | Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion Hit paper breakdown → | 2020 | 1078 |
| 4 | Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody Hit paper breakdown → | 2020 | 942 |
| 5 | Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS‐CoV) in SARS patients: implications for pathogenesis and virus transmission pathways Hit paper breakdown → | 2004 | 859 |
| 6 | Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses Hit paper breakdown → | 2020 | 691 |
| 7 | Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy Hit paper breakdown → | 2020 | 583 |
| 8 | Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein Hit paper breakdown → | 2020 | 561 |
| 9 | 1993 | 469 | |
| 10 | 2004 | 446 | |
| 11 | Recent advances in the detection of respiratory virus infection in humans Hit paper breakdown → | 2020 | 417 |
| 12 | AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells Hit paper breakdown → | 2021 | 382 |
| 13 | 2015 | 361 | |
| 14 | 2004 | 347 | |
| 15 | Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor Hit paper breakdown → | 2014 | 336 |
| 16 | 2006 | 331 | |
| 17 | 2020 | 324 | |
| 18 | 2020 | 273 | |
| 19 | 2020 | 266 | |
| 20 | Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses Hit paper breakdown → | 2022 | 259 |
About Shi Jiang
Shi Jiang is a scholar working on Infectious Diseases, Virology, Animal Science and Zoology, Immunology and Epidemiology, having authored 585 papers that have together received 34.9k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (205 papers), HIV Research and Treatment (189 papers), HIV/AIDS drug development and treatment (131 papers), Animal Virus Infections Studies (98 papers), COVID-19 Clinical Research Studies (80 papers), Viral gastroenteritis research and epidemiology (72 papers), Influenza Virus Research Studies (65 papers) and Monoclonal and Polyclonal Antibodies Research (63 papers). The work is most often cited by research in Infectious Diseases (22.7k citations), Virology (4.9k citations), Animal Science and Zoology (4.5k citations), Immunology (4.6k citations) and Modeling and Simulation (886 citations). Shi Jiang has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Lanying Du, Shuwen Liu, Lu Lu, Yusen Zhou, Yuxian He, Hong Lü, Shuai Xia, Asim Kumar Debnath, Tianlei Ying and Wei Xu. Their work appears in journals such as Journal of Virology, Viruses, Microbes and Infection, Biochemical and Biophysical Research Communications and Journal of Medicinal Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.